Matt Stuckert

Chief Commercial Officer (CCO) | Medical Device, MedTech, SaaS | Sales & Marketing Executive | President & General Manager

📍 United States🔄 Updated September 2026💼 2 investments📅 11 years investing🗓 Last invested Nov 2022
Angel investor🌍 United States
2
Total investments
1
Early stage
0
Mid stage
0
Late stage
11y
Years active

Portfolio

1 investments · sorted by recency
All investments
Early stage
Mid stage
Late stage
Technical Advisory Board Member & Investor
Jan 2015
Lineus Medical™ focuses on increasing the patients overall quality of care during IV therapy. We provide a safe solution to reduce overall IV complications requiring an IV restart. Our SafeBreak™ Vascular device utilizes a patented "break-away" technology to create a separation in the IV tubing. Before securement and adhesives fail, the SafeBreak Vascular separates. This preserves the IV access line from becoming dislodged, which can lead to blood loss and infection. In a matter of minutes, a medical care giver can remove the separated SafeBreak Vascular and replace it with a new one so that the patients medical treatment can resume.
Experience · 2 entries
All (2)
Investments (2)
2022
Advisor & Investor
Nov 2022
Magnolia Medical Technologies is on a Mission to ZERO®. Today, we offer healthcare institutions a solution to some of their biggest hidden problems – contamination leading to misdiagnosis of bloodstream infections, including sepsis, which can lead to unnecessary and prolonged antibiotic therapy, and false-positive CLABSIs. Tomorrow, we aspire to create a world free of in-vitro diagnostic errors where rapid, accurate test results improve the lives of patients and providers alike. We know that setting new standards of care is a journey enabled by purposeful innovation, partnerships, and perseverance. As the first step of our journey, we have successfully developed and proven our evidence-based technology platform, Steripath, which we’ve coupled with unparalleled support to change clinical practices and prevent unnecessary patient harm as well as system-wide costs associated with the misdiagnosis of sepsis. Our mission is further enabled by reducing false-positive CLABSIs and leveraging our extensive intellectual property portfolio – consisting of over 100 issued method, apparatus, and design patents and 70+ patent applications pending – to address other important sources of diagnostic error that are harmful to patients and costly to hospitals.
2015
Technical Advisory Board Member & Investor
Jan 2015
Lineus Medical™ focuses on increasing the patients overall quality of care during IV therapy. We provide a safe solution to reduce overall IV complications requiring an IV restart. Our SafeBreak™ Vascular device utilizes a patented "break-away" technology to create a separation in the IV tubing. Before securement and adhesives fail, the SafeBreak Vascular separates. This preserves the IV access line from becoming dislodged, which can lead to blood loss and infection. In a matter of minutes, a medical care giver can remove the separated SafeBreak Vascular and replace it with a new one so that the patients medical treatment can resume.